Z. Tomasevic

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial

Gϋnter von Minckwitz, Marco Colleoni, Hans‐Christian Kolberg et al. · The Lancet Oncology · 2018 · 98 citations

Medicine, Oncology, Pharmacology +8

Gray-Level Co-Occurrence Matrix Texture Analysis of Breast Tumor Images in Prognosis of Distant Metastasis Risk

Tijana Vujasinović, Jelena Pribic, Ksenija Kanjer et al. · Microscopy and Microanalysis · 2015 · 51 citations

Medicine, Oncology, Pathology +17

Cancer Control in Central and Eastern Europe: Current Situation and Recommendations for Improvement

Eduard Vrdoljak, G. Bodoky, Jacek Jassem et al. · The Oncologist · 2016 · 51 citations · Full text

Medicine, Health Policy, Oncology +17

Factor V Leiden mutation and high FVIII are associated with an increased risk of VTE in women with breast cancer during adjuvant tamoxifen — Results from a prospective, single center, case control study

Mirjana Kovač, Zeljko Kovac, Z. Tomasevic et al. · European Journal of Internal Medicine · 2015 · 35 citations

Medicine, Genetics, Oncology +11